You are here:

Archived: Biphasic insulin aspart 30 (Novomix 30®)


Not recommended for use within the NHS in Scotland.


This drug reduces blood sugar to a greater extent after breakfast and evening meal, but to a lesser extent after lunch, than existing treatment. It has no clear advantage in terms of global glycaemic control as demonstrated by HbA1c. There is no reduction in hypoglycaemic episodes to justify the overall increase in cost.

Drug Details

Drug Name: Biphasic insulin aspart 30 (Novomix 30®)
SMC Drug ID: 06/02
Manufacturer: Novo Nordisk Ltd
Indication: Diabetes mellitus
BNF Category:
Sub Category: 6.1 Drugs used in diabetes
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 5 July 2002

Current Advice

Resubmission 6 June 2003